There is little to no information on the impact on pregnancy of therapies approved to manage fibromyalgia nerve pain, a study has found. Because of this lack of data, the decision on whether to continue these therapies during pregnancy should be carefully considered, researchers suggest.
The review study, “Managing fibromyalgia syndrome in pregnancy no bridges between USA and EU,” was published in the journal Archives of Women’s Mental Health.
Fibromyalgia is characterized by generalized chronic pain, so it is mainly recognized as a pain disorder, at least in the rheumatology and pain communities. In other clinical fields, fibromyalgia has been perceived as a symptomatic or psychosomatic disorder, meaning a physical disease caused by mental factors.
Previous studies have reported that various psychiatric conditions, including mood and anxiety disorders, can coexist with fibromyalgia. Specifically, reports have noted that 20-80% of fibromyalgia patients experience major depression, while many patients may also have persistent depressive disorder (dysthymia) and generalized anxiety disorder.
Issue 12, Volume 5